GO
Loading...

Pharmaceuticals

More

  • UPDATE 1-Teva makes $82 per share offer for Mylan Tuesday, 21 Apr 2015 | 8:57 AM ET

    TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and cash.

  • *Global nutraceutical market seen at $280 bln by 2018. LONDON, April 21- A boom in "nutraceuticals"- food and drinks with potential health benefits- is paving the way for a rush of deals, as food and drug companies compete to dominate a market expected to be worth $280 billion by 2018.. "The space is ripe for M&A and I think you are going to see more," added Jeremy Johnson,...

  • Asian stocks mostly higher as Japan exports improve Tuesday, 21 Apr 2015 | 12:31 AM ET

    TAKING IT ALL IN: "It seems the market is in a holding pattern as investors are waiting to see just how much the dollar impacts corporate earnings," said Russell Price, Ameriprise Financial's senior economist. The chemical giant also lowered its forecast for full-year profits, and its stock fell $2.15, or 3 percent, to $70.70. CLEANING UP: Kimberly-Clark jumped 4...

  • Big biotech movers: Juno & Kite   Monday, 20 Apr 2015 | 2:42 PM ET
    Big biotech movers: Juno & Kite

    Shares of Juno Therapeutics and Kite Pharmaceuticals are falling today based on news coming out of a big cancer conference over the weekend, reports CNBC's Meg Tirrell.

  • NEW YORK— Israeli drugmaker Teva Pharmaceutical Industries said Monday that it will pay $512 million to resolve lawsuits accusing its Cephalon division of making illegal payments that kept cheaper generic versions of its sleep disorder drug Provigil off the market, boosting Cephalon's sales. The company set aside $495 million in 2013 to cover potential...

  • Promising cancer drugs   Friday, 17 Apr 2015 | 4:42 PM ET
    Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • Shares of Mylan NV rose $2.98, or 4.5 percent, to $69.82. Earlier this month Mylan offered to buy generic drug and ingredients maker Perrigo for about $29 billion, or $205 per share. Perrigo, which is based in Ireland, said it would review Mylan's offer.

  • Mylan: Fully committed to stand alone strategy   Friday, 17 Apr 2015 | 2:50 PM ET
    Mylan: Fully committed to stand alone strategy

    CNBC's Dominic Chu reports the latest on Mylan and their pending acquisition of Perrigo.

  • Teva considering potential bid for Mylan - Bloomberg Friday, 17 Apr 2015 | 2:37 PM ET

    April 17- Teva Pharmaceuticals Industries is considering a bid for Mylan NV, Bloomberg reported, citing people familiar with the matter. Teva has not made a formal approach, Bloomberg reported. Generic drugmaker Mylan offered to buy Perrigo Co Plc for about $29 billion in cash and stock in early April.

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Teva considering bid for Mylan: DJ   Friday, 17 Apr 2015 | 2:25 PM ET
    Teva considering bid for Mylan: DJ

    CNBC's Meg Tirrell provides insight to a report on Teva Pharmaceutical Industries Ltd. exploring a takeover offer from Mylan.

  • Glaxo recalls flu vaccine due to potency problem Friday, 17 Apr 2015 | 1:24 PM ET

    WASHINGTON— GlaxoSmithKline is recalling remaining doses of a popular four-in-one flu vaccine because of effectiveness problems. But Glaxo said in a letter it "cannot rule out potential suboptimal protection" in people who received the vaccine in early January or later. More than 99 percent of the vaccines were distributed in 2014, before the product began...

  • The generic, called Glatopa, is made by Sandoz, a unit of Swiss drug company Novartis AG, and U.S.-based Momenta Pharmaceuticals. The Food and Drug Administration approved the drug Thursday. But Teva Pharmaceutical Industries, which makes Copaxone, has said it expects generic versions of the drug to go on sale in the U.S. in September.

  • A promising treatment from Bristol-Myers Squibb may be fast-tracking toward another approved use after researchers stopped a study early because the drug did better than an older treatment in patients with an advanced form of lung cancer. Shares of the New York drugmaker jumped Friday morning after it said Opdivo fared better than the chemotherapy drug...

  • Exciting time for drug breakthroughs: Merck CEO   Thursday, 16 Apr 2015 | 2:12 PM ET
    Exciting time for drug breakthroughs: Merck CEO

    Ken Frazier, Merck Chairman & CEO, discusses challenges facing the healthcare industry and the launch of new medicines. We will see great drugs going forward, says Frazier.

  • Need to change the laws on corporate tax: Pfizer CEO

    Ian Read, Pfizer Chairman & CEO, discusses accomplishments and breakthroughs that have taken place in the past year in the pharmaceuticals sector and gives a read on taxes.

  • The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...

  • April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...

  • LONDON, April 16- Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to extend lives for prostate cancer sufferers. Ipsen stock was down 10 percent in early trade while Active Biotech, which originally developed the drug, slumped 60 percent.

  • LONDON, April 16- Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to extend lives for prostate cancer sufferers. As a result, the companies said they had decided to discontinue all studies of tasquinimod in prostate cancer, torpedoing sales...